Table 2.

Associations Between Patient Characteristics and Survival

Characteristic	Hazard Ratio (95% CI)	p value
Univariable association
Age: < 65 vs. > 65	1.18 (0.65–2.18)	.58
ECOG: 1 vs. 0	1.67 (0.91–3.07)	.1
Tumor location: head vs. other	1.4 (0.65–3.04)	.39
Tumor resection: whipple vs. distal and total	1.24 (0.52–2.93)	.63
Gender: female vs. male	1.58 (0.87–2.9)	.14
Pathology: poorly differentiated vs. other	1.62 (0.88–2.93)	.13
Margin: negative vs. positive	1.12 (0.62–2.05)	.7
Staging: node positive vs. negative	2.28 (0.55–9.45)	.26
Tumor size/per cm increase	1.2 (0.99–1.45)	.06
Lymph count at 2 months: < 500 vs. 500**	1.82 (0.995–3.3)	.05
Baseline lymphocyte count* < 1,000 vs. ≥ 1,000	1.58 (0.56–4.41)	.39
Baseline AST	1.002 (0.99–1.03)	.86
Baseline BUN	1.007 (0.95–1.07)	.84
Baseline CA19-9	1.002 (0.999–1.01)	.17
Baseline albumin	0.86 (0.44–1.68)	.67
Baseline alkaline phosphatase	1.001 (0.999–1.0)	.35
Chemotherapy: 5-fU vs. gemcitabine based	0.84 (0.46–1.55)	.58
Multivariable association
Lymph count at 2 months: < 500 vs. ≥ 500	2.20 (1.17–4.12)	.01
Baseline lymph count: < 1,000 vs. ≥ 1,000	3.06 (1–9.14)	.05
Staging: node positive vs. negative	3.79 (0.86–16.67)	.08

^*Pretreatment lymphocyte count is dichotomized at 1,000 (abnormal vs. normal).

^**Lymphocyte count at 2 months is dichotomized at 500 (per the CTC NIH grade 3–4 treatment induced lymphopenia).